Revolution Medicines to Report Financial Results for First Quarter 2023 After Market Close on May 8, 2023

May 1, 2023

REDWOOD CITY, Calif., May 01, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that it will report financial results for the first quarter 2023 on Monday, May 8, 2023, after market close. At 4:30 p.m. Eastern Time that day (1:30 p.m. Pacific Time), Revolution Medicines' senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress.

To listen to the live webcast, or access the archived webcast, please visit: https://ir.revmed.com/events-and-presentations. Following the live webcast, a replay will be available on the company's website for at least 14 days.

About Revolution Medicines, Inc.
Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. The company's RAS(ON) Inhibitors RMC-6236 (RAS ^{MULTI}) and RMC-6291 (KRAS^{G12C}) are currently in clinical development. Additional RAS(ON) Inhibitors in the company's pipeline include RMC-9805 (KRAS ^{G12D}) and RMC-0708 (KRAS^{Q61H}), both of which are currently in IND-enabling development, RMC-8839 (KRAS^{G13C}), and additional compounds targeting other RAS variants. RAS Companion Inhibitors currently in clinical development include RMC-4630 (SHP2) and RMC-5552 (mTORC1/4EBP1).

Investors & Media Contact: Erin Graves 650-779-0136 egraves@revmed.com